Regulatory Novartis secures pair of regulatory wins for skin disease and malaria treatments Pharmaceutical TechnologyNovartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaceutical Technology Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New NIHR-funded TRC for Parkinson’s diseaseNext: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis Related Stories Regulatory FDA delays verdict on AZ breast cancer drug pharminent May 27, 2026 Regulatory Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC pharminent May 26, 2026 Regulatory Bayer gets swift review for Kerendia in type 1 diabetes pharminent May 21, 2026
